The Amplify-7P study, designed to evaluate the efficacy of ELA-002 7P as an adjuvant treatment, missed its prespecified target for disease-free survival. Despite the primary failure, the company noted that post-hoc analyses identified a more robust therapeutic signal among the 84% of participants who underwent complete tumor resection with clear surgical margins. Elicio management indicated these insights are now being used to sharpen the focus of a planned phase 3 strategy, which will incorporate adjusted dosing regimens. To support these future efforts, the biotechnology firm is actively exploring strategic financing and potential partnership opportunities to bankroll subsequent late-stage testing.